Antimicrobial resistance is on the rise. Neisseria gonorrhea (NG) — also known as Gonococcus (GC) — already developed resistance to multiple classes of antibiotics and is classified as “urgent threat” by the Centers for Disease Control and Prevention.1 Today, advances in testing can enable more accurate treatment, and aims to help healthcare professionals preserve last-line antibiotics for future use.
Through a partnership with SpeeDx, a developer of innovative molecular diagnostic solutions, Roche is ushering in a new era of resistance-focused diagnostics.